# Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma

> **NCT00083577** · PHASE2 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 250 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00083577
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-02
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 250 (—)
- **Last updated:** 2010-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083577, "Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00083577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*